Chronic Obstructive Pulmonary Disease News and Research

Latest Chronic Obstructive Pulmonary Disease News and Research

Forest Laboratories second quarter net sales increase 7.7% to $1,037.3 million

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, announced that diluted earnings per share equaled $1.00 in the second quarter of fiscal 2011.

19 Oct 2010

ERS calls Europeans for lung test on World Spirometry Day

With new data revealing 23 Europeans die each hour from a preventable lung condition, the European Respiratory Society (ERS) is calling on people across Europe to get their lungs tested on the first ever World Spirometry Day 14th October.

14 Oct 2010

VNSNY adopts advanced information technology to improve patient care

Unlike most home healthcare agencies, which have restricted the use of computer programs to such non-patient-care items as billing, the Visiting Nurse Service of New York has adopted advanced information technology in order to improve patient care. One of the results, documented in a new publication, is a significant 10% reduction in patient episodes ending in hospitalization, from 37% to 27% over the years 2001-2009.

12 Oct 2010

Valeant announces Alexza's receipt of FDA CRL for AZ-004 NDA

Valeant Pharmaceuticals International, Inc. announced today that Alexza Pharmaceuticals, Inc. has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding Alexza's New Drug Application (NDA) for AZ-004 (Staccato® loxapine) submitted as Adusuve™ Staccato® (loxapine) inhalation aerosol, 5 mg and 10 mg.

11 Oct 2010

Researchers develop new technique to detect lung cancer

Early detection is critical for improving cancer survival rates. Yet, one of the deadliest cancers in the United States, lung cancer, is notoriously difficult to detect in its early stages.

8 Oct 2010

Optical technology shows potential for prescreening patients at high risk for lung cancer

Researchers from Northwestern University and NorthShore University HealthSystem (NorthShore) have developed a method to detect early signs of lung cancer by examining cheek cells in humans using pioneering biophotonics technology.

6 Oct 2010

Amino acid mixture increases survival in mice

When mice are given drinking water laced with a special concoction of amino acids, they live longer than your average mouse, according to a new report in the October issue of Cell Metabolism, a Cell Press publication. The key ingredients in the supplemental mixture are so-called branched-chain amino acids, which account for 3 of the 20 amino acids (specifically leucine, isoleucine, and valine) that are the building blocks of proteins.

6 Oct 2010

New equation to calculate energy requirement for underweight COPD patients

Malnutrition often goes hand in hand with COPD and is difficult to treat. In a recent study researchers at the University of Gothenburg, have come up with a new equation to calculate the energy requirement for underweight COPD patients. It is hoped that this will lead to better treatment results and, ultimately, better quality of life for these patients.

4 Oct 2010

Study shows regadenoson is safe and effective for chronic lung disease

Patients at risk of coronary disease who have reactive airways may breathe easier thanks to new data released today at the 15th Annual Scientific Session of the American Society of Nuclear Cardiology. A new study shows that regadenoson may be safely tolerated by patients with chronic lung disease, providing an alternative to adenosine, which is known to induce brochoconstriction in some patients.

27 Sep 2010

Clinical Data announces Stedivaze agonist data at ASNC2010 meeting

Clinical Data, Inc., today presented data from Phase I studies of Stedivaze (apadenoson), which demonstrated overall safety and tolerability in patients with asthma and chronic obstructive pulmonary disease (COPD).

27 Sep 2010

Astellas Pharma announces Phase IV study results of Lexiscan injection at ASNC session

Today Astellas Pharma US, Inc. announced results of a Phase IV study showing Lexiscan(regadenoson) Injection was comparable to placebo in causing a >15% decrease in forced expiratory volume in one second (FEV1) in subjects with asthma or chronic obstructive pulmonary disease (COPD) who are likely candidates for myocardial perfusion imaging (MPI) studies.

27 Sep 2010

Dual eligible patients more likely to be hospitalized than Medicare beneficiaries: AHRQ

Americans who were eligible for coverage under both Medicare and Medicaid in 2008 were hospitalized for bed sores, asthma and diabetes at more than twice the rate of other Medicare beneficiaries, according to the latest News and Numbers from the Agency for Healthcare Research and Quality.

27 Sep 2010

ProtAffin presents impressive efficacy data for PA401 in COPD

ProtAffin AG, a biotechnology company developing a novel class of biopharmaceutical products that act by targeting cell-surface glycan structures, today presents compelling preclinical data in chronic obstructive pulmonary disease (COPD) for its lead product PA401 at the European Respiratory Society Congress in Barcelona, Spain. This conference is the largest gathering of scientists and clinicians in the respiratory community in the world. The Oral Presentation will be made in the session "Pre-clinical models of airways disease".

21 Sep 2010

Tiotropium bromide shows potential as an alternative asthma treatment

A drug commonly used for the treatment of chronic obstructive pulmonary disease (COPD) successfully treats adults whose asthma is not well-controlled on low doses of inhaled corticosteroids, reported researchers supported by the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health.

20 Sep 2010

HealthWyse, Cardiocom partner to integrate patient information into clinical software

HealthWyse, a leading provider of home health and hospice software and services, announced today that it has partnered with Cardiocom, a leader in home telehealth solutions, to seamlessly integrate patient information into HealthWyse's clinical software.

13 Sep 2010

Forest files response to FDA Complete Response Letter for roflumilast NDA

Forest Laboratories, Inc. today announced that it has filed a response to the U.S. Food & Drug Administration (FDA) addressing topics raised in the complete response letter regarding the New Drug Application (NDA) for roflumilast. Forest licenses roflumilast from Nycomed, which submitted the original NDA.

13 Sep 2010

Research finds immune system mechanism to minimize collateral damage

A study published today in the journal Science shows how our bodies try to minimise potential 'collateral damage' caused by our immune system when fighting infection. The research may also provide new clues to why cigarette smoke is a significant risk factor for developing diseases of the lung such as chronic bronchitis and emphysema.

3 Sep 2010

Californians recognized for contributing to plasma protein lifesaving therapies

This month, Californians are recognized for their outstanding contributions to lifesaving therapies that treat critically ill individuals and for their donations of the blood component, plasma, that makes the creation of these unique therapies possible.

3 Sep 2010

Cigarette smoke inhibits LTA4H enzyme, regulates body's response to inflammation: Study

Cigarette smoke shuts off a key enzyme in airways that regulates the body's response to inflammation, according to findings from the University of Alabama at Birmingham published online today at Science Express.

3 Sep 2010

Pharmacor 2010 findings predict COPD drug market rise to $13 billion in 2019

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues finds that, through 2019, an expanding aging population and increases in diagnosis and drug treatment will fuel steady 4.6 percent annual growth in the chronic obstructive pulmonary disease (COPD) drug market.

2 Sep 2010